Dapsone gel vs benzoyl peroxide for acne
Every row cites its source. Where a cell reflects our own reading of the evidence rather than an external source, the row says so.
The prescription sulfone against the default OTC active. No head-to-head trial exists, so this table refuses to invent one; it compares what is actually documented.
| Aspect | Dapsone gel | Benzoyl peroxide | Source |
|---|---|---|---|
| 2024 AAD guideline position | Not named in the strong or conditional recommendation lists of the guideline abstract | Strong recommendation | source |
| Regulatory route | Prescription only, both concentrations | OTC monograph active at 2.5 to 10 percent: legal without prescription | source |
| Head-to-head evidence | None exists: no monotherapy RCT against BPO has been published | Same absence; the one randomized combination study found adding BPO to dapsone gel did not beat adding moisturizer (P=0.052) | source |
| Interaction with each other | Concurrent use can temporarily stain skin and facial hair yellow or orange | Same label-documented interaction, from the BPO side | source |
| Tolerability | Trial side effects nearly identical to vehicle (dryness 1.1% vs 1.0%) | Classically drying and bleaching; benchmark comparative data: azelaic acid trials found BPO distinctly more irritating | source |
| Resistance | No resistance studies conducted in gel trials; M. leprae resistance documented with oral monotherapy | Resistance-sparing; commonly combined with antibiotics for that purpose | source |